@BioWorld

Biopharma’s trusted news source

 USA
bioworld.com/
Joined April 2009
  • Tweets48.2K
  • Following8.8K
  • Followers38.8K
479Media
Include

Only show posts containing:

Exclude

Hide posts containing:

Time range
-
Minimum likes
Alpha male in HS? @Abbvie phase III data subdue @Avalotx shares bioworld.com/articles/734846 #biopharma #HidradenitisSuppurativa #phaseIII

Alpha male in HS? Abbvie phase III data subdue Avalo shares​

Phase III news from competitor Abbvie Inc. in hidradenitis suppurativa (HS) put a sizeable dent in shares of Avalo Therapeutics Inc. (NASDAQ:AVTX), which ended Oct. 22 at $7.45, a loss of $4.81 or...

bioworld.com
36
UK opens national #Alzheimer’s trial to test approved, novel drugs bioworld.com/articles/734843 #biopharma @UKDRI

UK opens national Alzheimer’s trial to test approved, novel drugs

The U.K. is setting up a nationwide randomized, placebo-controlled, double-blind Alzheimer's disease trial, which will test multiple drugs in parallel, assessing the potential for repurposing...

bioworld.com
1
127
Will .@QIAGEN shareholders be tempted by @eqt’s €10.8B offer? (free w/one-time registration) bioworld.com/articles/734842 #medtech #MANDA #diagnostics

Will Qiagen shareholders be tempted by EQT's €10.8B offer?

EQT has signed an agreement to take Qiagen NV private, offering shareholders €46.50 a share in cash, in a deal with an enterprise value of approximately €10.8 billion (US$12.13 billion). Qiagen’s...

bioworld.com
138
Japan backs Nipro’s Stemirac for first full approval under CEA bioworld.com/articles/734845 #biopharma #regenerativemedicine #celltherapy #neurology #approval

Japan backs Nipro’s Stemirac for first full approval under CEA

Japan has backed Nipro Corp.’s Stemirac for full approval, about eight years after the mesenchymal stem cell therapy first won conditional approval in 2018. If approved, Stemirac will become the...

bioworld.com
186
#AusBiotech2026: Federated AI tackles drug discovery's data bottleneck bioworld.com/articles/734844 #biopharma #DrugDiscovery #AI #ArtificialIntelligence #AusBiotech2026

Federated AI tackles drug discovery's data bottleneck

The next breakthrough in artificial intelligence-driven drug discovery may depend less on more sophisticated algorithms than on unlocking decades of experimental data held by pharma companies and...

bioworld.com
198
UK to accept CE marked medical devices indefinitely bioworld.com/articles/734797 #medtech #CEmarked

UK to accept CE marked medical devices indefinitely

The U.K. government has said that it will continue to accept CE marked medical devices on a long-term basis following a public consultation that received more than 1,000 responses from patients,...

bioworld.com
1
2
457
Med-tech M&A value doubles despite 70% drop in acquisitions bioworld.com/articles/734796 #medtech #deals @Medtronic @TelixPharma @ITM_Radiopharma @enovismedtech @ecentialrobot

Med-tech M&A value doubles despite 70% drop in acquisitions

Med-tech M&A activity came to a halt in September 2026, with no transactions closing, marking the first zero-value month in BioWorld’s records going back to 2019. The slowdown followed $1.5 billion...

bioworld.com
3
545
.@Roivant, Priovant targeting #uveitis for next brepocitinib NDA bioworld.com/articles/734792

Roivant, Priovant targeting uveitis for next brepocitinib NDA

Roivant Sciences Ltd.’s plans for broadening the reach of recently approved TYK2/JAK1 inhibitor Lisraya (brepocitinib) got a boost on positive phase III data demonstrating solid efficacy in non-inf...

bioworld.com
1
5
760
Tissium secures CE mark for ventral hernia repair solution bioworld.com/articles/734795 #medtech #Eclipsium #CEmark #hernia

Tissium secures CE mark for ventral hernia repair solution

Tissium SA received CE mark certification for Eclipsium, its atraumatic mesh fixation solution for ventral hernia repair. It is the second product the company has secured regulatory approval for that...

bioworld.com
1
411
Ausbiotech2026: Australia urged to seize biotech opportunity amid US turmoil bioworld.com/articles/734793… #AustralianBiotech #Biotechnology #ClinicalTrials

Australia urged to seize biotech opportunity amid US turmoil

Australia must make biotechnology a strategic national industry and build on its clinical trial strengths as political pressure on U.S. scientific institutions and China’s rise reshape global drug...

bioworld.com
1
4
365
.@GSK’s Hibsago clears FDA bar as first ASO in chronic hepatitis B (free w/one-time registration) bioworld.com/articles/734791… #biopharma #hepatitisB #ASO #FDAapproval @ionispharma

GSK’s Hibsago clears FDA bar as first ASO in chronic hepatitis B

A day after securing accelerated approval of Jemperli (dostarlimab), GSK plc won U.S. FDA clearance for bepirovirsen under the brand name Hibsago, marking the first antisense oligonucleotide (ASO)...

bioworld.com
3
417
#UEGWeek: Early antibiotic exposure linked to IBS in adulthood (free w/ registration) bioworld.com/articles/734808… #gastrointestinal #preclinical #research #science #news

Early antibiotic exposure linked to IBS in adulthood

At the United European Gastroenterology Week (UEGW) 2026 annual conference being held in Barcelona Oct. 17-20, a team of researchers from the Karolinska Institutet, the Sahlgrenska University...

bioworld.com
1
2
206
.@GSK’s #Jemperli wins accelerated nod in rectal cancer bioworld.com/articles/734861… #cancer #approval

GSK’s Jemperli wins accelerated nod in rectal cancer

Beating other PD-1 therapies to the finish line, GSK plc’s Jemperli (dostarlimab) secured accelerated approval from the U.S. FDA as the first immunotherapy for use in treating adults with with stage...

bioworld.com
4
506
‘Meme stock phenomenon’ at play in Cassava class action bioworld.com/articles/734777 #biopharma #CassavaSciences #ClassAction #FifthCircuit #FilanaTherapeutics #MemeStock

‘Meme stock phenomenon’ at play in Cassava class action

Although a mediated settlement is already on the table awaiting court approval, the U.S. Court of Appeals for the Fifth Circuit breathed new life into Cassava Sciences Inc.’s fight to stave off a...

bioworld.com
1
375
Rapport’s RAP-219 wins in bipolar mania, heads to phase III (free w/one-time registration) bioworld.com/articles/734776 #biopharma #bipolar #seizures #psychology

Rapport’s RAP-219 wins in bipolar mania, heads to phase III

Hitting statistical significance and proof of concept in phase II for bipolar mania, Rapport Therapeutics Inc. is moving to phase III with its TARPγ8-specific AMPA receptor negative allosteric...

bioworld.com
4
429
.@Labcorp #acquisition spree continues bioworld.com/articles/734860…

Labcorp acquisition spree continues

Labcorp Holdings Inc. appears to be on an acquisition spree. It has agreed to buy the Prenatal Health testing business of Myriad Genetics Inc. for $210 million in cash, just days after announcing an...

bioworld.com
2
520
.@AbbottNews secures CE mark certification for #Cologuard Plus bioworld.com/articles/734781… #diagnostic #cancers

Abbott secures CE mark certification for Cologuard Plus

Abbott Laboratories received CE mark certification for the Cologuard Plus, a stool-based DNA test designed to detect both colorectal cancer and advanced precancerous lesions. The test was developed...

bioworld.com
4
467
Alzheimer’s blood tests mean earlier diagnosis, new type of patient bioworld.com/articles/734780 #biopharma #medtech #Alzheimers #diagnostics @WorldDementia

Alzheimer’s blood tests mean earlier diagnosis, new type of patient

New blood-based biomarker tests that detect Alzheimer’s before symptoms appear are poised to transform the clinical landscape by catching the disease when controlling for risk factors is known to...

bioworld.com
1
341
.@EliLillyandCo’s delivery tech search continues with $1B Metis deal bioworld.com/articles/734779 #biopharma #deal #AI #drugdelivery #LNP

Lilly’s delivery tech search continues with $1B Metis deal

Eli Lilly and Co. partnered with Metis Techbio Co. Ltd. under a potential $1 billion-plus deal to codevelop novel lipid nanoparticle-based delivery solutions, using Metis’ AI-powered LNP platform.

bioworld.com
401
ADC frenzy continues with $15B+ @Roche-Hansoh deal (free w/one-time registration) bioworld.com/articles/734778 #biopharma #oncology #ADC #lungcancer #deal

ADC frenzy continues with $15B+ Roche-Hansoh deal

Roche Holding AG turned once again to Jiangsu Hansoh Pharmaceutical Group Co. Ltd. to source novel antibody-drug conjugates (ADCs), including two of Hansoh’s preclinical programs, in a deal that...

bioworld.com
2
572
Load more